Psilera Inc.

Cybin’s New US Patent Covers Proprietary Deuterated Psychedelic Analogs Clinical-stage biotech company Cybin Inc. (NYSE: CYBN) received a U.S. patent covering composition of matter claims for deuterated tryptamines, including the novel psilocybin analog in the company’s CYB003...

Next-generation R&D psychedelics company Psilera Inc. shared its two proprietary DMT analogs PSIL-001 and PSIL-002’s preclinical positive results for mental health disorder treatments.  Psilera uses machine-learning methods to map complex datasets and identify early-stage lead...

Psilera Inc., a Florida-based biotech company specializing in the psychedelics sector, announced a “research and development agreement” with the National Institute on Drug Abuse (NIDA) for the launch of a series of preclinical studies on Psilera’s psychedelic drug pipeline. The...